Kymera Therapeutics, Inc.(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced an update to its IRAK4 partnership with Sanofi.

Kymera Therapeutics, Inc. (NASDAQ: KYMR)，一家临床阶段的生物制药公司，正在推进一类用于免疫疾病的新口服小分子降解药物，今天宣布了与赛诺菲关于IRAK4合作的更新。

Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance into clinical studies. Following extensive preclinical work supporting its robust development potential, KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration, and is expected to advance into Phase 1 testing next year.

赛诺菲已通知凯米拉公司，KT-485/SAR447971是一种口服、高效且选择性开发的候选药物，针对IRAK4用于免疫炎症性疾病，凯米拉通过临床前研究发现了并描述了该药物，现已选定进入临床研究阶段。在广泛支持其强大开发潜力的临床前工作之后，KT-485正在双方现有的IRAK4合作框架下被优先开发，并预计于明年进入第一阶段测试。

Based on the planned development of KT-485, Sanofi will not advance KT-474..

基于KT-485的计划开发，赛诺菲将不会推进KT-474。

In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the terms of the companies’ collaboration agreement. Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485.

赛诺菲在推进KT-485计划的同时，还宣布了根据双方合作协议条款行使对IRAK4靶点参与选择权的决定。根据协议，Kymera在2025年第二季度达成了与KT-485相关的临床前活动的2000万美元里程碑。

Kymera is eligible to receive up to $975 million of potential clinical, regulatory and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing..

Kymera 有资格获得与 KT-485 相关的高达 9.75 亿美元的潜在临床、监管和商业里程碑，其中包括在 1 期临床试验开始时的额外里程碑。

“Sanofi’s intention to advance KT-485 into clinical testing and to direct all collaboration resources to the next-generation IRAK4 degrader is a reflection of the molecule’s compelling preclinical profile and of Sanofi’s and Kymera’s commitment to transform immunology treatment paradigms. Both companies have a strong belief in and commitment to targeting the IRAK4 pathway with degraders that are functionally differentiated from small molecule inhibitors, and to bringing forward the best oral medicines to patients living with immunological diseases,” commented Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics.

“赛诺菲打算将KT-485推进到临床试验，并将所有合作资源集中于下一代IRAK4降解剂，这反映了该分子令人信服的临床前特性，以及赛诺菲和Kymera致力于改变免疫学治疗模式的决心。两家公司都坚信并承诺通过功能上不同于小分子抑制剂的降解剂来靶向IRAK4通路，并为患有免疫疾病的患者带来最佳口服药物。” Kymera Therapeutics创始人、总裁兼首席执行官Nello Mainolfi博士评论道。

“In preclinical testing, KT-485 demonstrated an improved target product profile as compared to KT-474. With greater potency and selectivity and a generally improved overall profile, KT-485 is best-positioned to capitalize on the significant potential of IRAK4 degradation.”.

“在临床前测试中，与 KT-474 相比，KT-485 展现出更优越的目标产品特性。凭借更强的效力和选择性以及整体改善的特性，KT-485 最有能力充分利用 IRAK4 降解的巨大潜力。”

About KT-485

关于KT-485

KT-485/SAR447971 is a first-in-class, selective, potent, oral IRAK4 degrader in development for the treatment of immuno-inflammatory diseases with significant patient need. IRAK4 is a master regulator of innate immunity and key protein of the myddosome complex that mediates signaling through IL-1 and toll-like receptors.

KT-485/SAR447971是一种首创的、选择性的、强效的口服IRAK4降解剂，正在开发用于治疗有显著患者需求的免疫炎症性疾病。IRAK4是先天免疫的主调控因子，也是介导IL-1和Toll样受体信号传导的myddosome复合物的关键蛋白。

IRAK4 is a scaffolding kinase that acts at the interface of the innate and adaptive immune responses with a variety of functions depending on its kinase activity and scaffolding function. Eliminating IRAK4 completely through degradation impacts both the kinase and scaffolding functions, therefore having the potential to achieve a broad, well-tolerated, anti-inflammatory effect providing a novel therapeutic approach for a variety of immune-inflammatory diseases.

IRAK4是一种支架激酶，在先天性和适应性免疫反应的界面上发挥作用，其功能多样性取决于其激酶活性和支架功能。通过降解完全消除IRAK4会影响激酶和支架功能，因此有可能实现广泛、耐受性良好的抗炎效果，为多种免疫炎症性疾病提供了新颖的治疗途径。

Clinical data generated to date demonstrates the potential of IRAK4 degradation to deliver the combined activity of upstream biologics in an oral drug for multiple diseases. Sanofi, which is collaborating with Kymera on the development of IRAK4 degraders outside of the oncology and immuno-oncology fields, is progressing the IRAK4 program through clinical development. Per the collaboration, Kymera achieved a $20 million milestone related to preclinical activities associated with KT-485.

迄今为止生成的临床数据表明，IRAK4降解有望在一款口服药物中实现上游生物制品的联合活性，用于治疗多种疾病。赛诺菲正与Kymera合作开发非肿瘤学和免疫肿瘤学领域的IRAK4降解剂，并正在推进IRAK4项目进入临床开发阶段。根据合作协议，Kymera达成了与KT-485相关的2000万美元临床前活动里程碑。

Kymera is eligible to receive an additional milestone upon the start of Phase 1 clinical testing, part of up to $975 million of potential clinical, regulatory and commercial milestones..

Kymera 有资格在第一阶段临床测试开始时获得额外的里程碑，这是潜在的临床、监管和商业里程碑中的一部分，总额可能高达 9.75 亿美元。

About Kymera Therapeutics

关于凯米拉治疗学

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.

Kymera是一家处于临床阶段的生物技术公司，率先在靶向蛋白降解（TPD）领域开展研究，致力于开发解决关键健康问题并有潜力显著改善患者生活的药物。Kymera正在利用TPD技术针对传统疗法无法触及的疾病靶点和通路进行研究。

Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Kymera 已将首个降解剂推进到免疫疾病领域的临床阶段，目前正专注于构建一条行业领先的口服小分子降解剂管线，为这些疾病的患者提供新一代便捷且高效的治疗方案。自2016年成立以来，Kymera 连续多年被评为波士顿最佳工作场所之一。